Quest Diagnostics (DGX) Q4 2022 Earnings Call Transcript

Quest Diagnostics Incorporated (NYSE:DGX) Q4 2022 Earnings Conference Call February 2, 2023 8:30 AM ET

Company Participants

Jim Davis - President, Chief Executive Officer

Sam Samad - Executive Vice President, Chief Financial Officer

Shawn Bevec - Vice President, Investor Relations

Conference Call Participants

Ann Hynes - Mizuho Securities

Patrick Donnelly - Citi

Jack Meehan - Nephron Research

AJ Rice - Credit Suisse

Pito Chickering - Deutsche Bank

Brian Tanquilut - Jefferies

Kevin Caliendo - UBS

Andrew Brackmann - William Blair

Derik de Bruin - Bank of America

Elizabeth Anderson - Evercore ISI

Rachel Vatsndal - JP Morgan

Operator

Welcome to the Quest Diagnostics Fourth Quarter and Full Year 2002 conference call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and question and answer session that will follow are copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution of retransmission of the rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited.

Now I’d like to introduce Shawn Bevec, Vice President, Investor Relations for Quest Diagnostics. Please go ahead.

Shawn Bevec

Thank you and good morning. I’m joined by Jim Davis, our Chief Executive Officer and President, and Sam Samad, our Chief Financial Officer.

During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties, including the impact of the COVID-19 pandemic, that may affect Quest Diagnostics’ future results include but are not limited to those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.

For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS. Any references to base business, testing, revenues or volumes refer to the performance of our business excluding COVID-19 testing. Growth rates associated with our long term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth are compound annual growth rates. Finally, revenue growth rates from acquisitions will be measured against our base business.

Now here is Jim Davis.

Jim Davis